The human antigen-binding protein (beta)-Klotho, the fibroblast growth factor (FGF) receptor, and its complexes.

TH2501008820APending Publication Date: 2026-04-20AMGEN INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TH2501008820
Authority / Receiving Office
TH · TH
Patent Type
Applications
Current Assignee / Owner
Priority Date
2010-12-03
Filing Date
2010-12-03
Publication Date
2026-04-20

Smart Images

  • Figure 2501008820_DRAWING_01
    Figure 2501008820_DRAWING_01
  • Figure 2501008820_DRAWING_02
    Figure 2501008820_DRAWING_02
  • Figure 2501008820_DRAWING_03
    Figure 2501008820_DRAWING_03
Patent Text Reader

Abstract

DEPCT69 This invention provides the composition and methods associated with or derived from antigen-binding proteins that induce fibroblast growth factor 21 (FGF21)-mediated signaling. In some formulations, the antigen-binding protein will specifically bind to (i) beta-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c, or FGFR4; or (iii) a complex composed of beta-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some formulations, the antigen-binding protein will induce FGF21-like signaling. In some formulations, the antigen-binding protein is a fully human antibody, a humanized antibody, or a chimeric antibody, or a binding fragment. and derivatives of such antibodies, and polypeptides that specifically bind to (i) beta-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4;or (iii) complexes containing beta-Klotho and one of FGFR1c, FGFR2c, FGFR3c and FGFR4, other variants providing nucleic acids that encode the antigen-binding proteins, and their fragments and derivatives, and polypeptides, cells containing such polypeptides, methods for generating the antigen-binding proteins, and their fragments and derivatives, and polypeptides, including methods for the treatment or diagnosis of patients suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions;
Need to check novelty before this filing date? Find Prior Art

Claims

DEPCT69 1. A modified antibody or fragment of the thing capable of binding to a complex comprising beta-klotho and fibroblast growth factor receptor 1c (FGFR1c), and inducing fibroblast growth factor 21 (FGF21) signaling, in which such modified antibody or fragment of the thing comprises: an amino acid sequence that is 90% identical to SEQ ID NO: 50 and comprises an amino acid sequence that is 90% identical to SEQ ID NO:

68.

2. A modified antibody or fragment of the thing of claim 1, in which such modified antibody Or a fragment of such thing comprises: an amino acid sequence that is 95% identical to SEQ ID NO: 50 and comprises an amino acid sequence that is 95% identical to SEQ ID NO:

68.

3. A modified antibody or fragment of such thing of Claim 2, where the modified antibody or fragment of such thing comprises SEQ ID: 50 and SEQ ID:

68. 4.A pharmaceutical component consisting of a modified antibody or fragment of that of any one of the claims of claims 1 through 3 in an admixture with its pharmaceutically acceptable carrier.